Shire Pharmaceuticals Group plc
Hampshire International Business Park,
Chineham, Basingstoke RG24 8EP UK
Tel +44 1256 894000 Fax +44 1256 894708
http://www.shire.com
(COMPANY'S LOGO)
For immediate release May 15, 2002
13:30 noon BST - 8:30 am EST
NEW ADDERALL XR(TM)DATA TO BE PRESENTED AT THE AMERICAN PSYCHIATRIC ASSOCIATION
(APA) MEETING IN PHILADELPHIA
Basingstoke, UK - 15 May 2002 - Shire Pharmaceuticals Group plc (LSE: SHP,
NASDAQ: SHPGY, TSX: SHQ) announces a number of events of interest to the
investment community during the 155th Annual American Psychiatric Association
Meeting taking place in Philadelphia, PA, from May 18 - 23, 2002.
APA Events
On Tuesday May 21, Dr. Mark C. Chandler will present an 18-month interim
analysis of an ongoing, multicenter, open-label extension trial involving
Adderall XR treatment. The purpose of this trial was to assess the long-term
safety and efficacy of Adderall XR therapy.
On Wednesday May 22, Dr. Paul J. Ambrosini will present a prospective,
open-label study which enrolled approximately 3000 children diagnosed with ADHD,
taking stable doses of immediate-release AdderallTM, or any methylphenidate
formulation. The purpose of this trial was to evaluate the tolerability and
effectiveness of Adderall XR in the treatment of pediatric ADHD in the community
practice setting.
On Wednesday May 22, Dr. Joseph Biederman and a panel of physicians will conduct
a symposium entitled, "Adult ADHD: From Research to Clinical Practice". The
panelists will discuss the issues involved in the diagnosis and treatment of
adult ADHD.
Shire Investor Meeting
Shire will also be hosting a meeting in Philadelphia for the investment
community on Wednesday May 22, 2002 from 5:30pm to 6:30pm ET (10:30pm to 11:30pm
GMT) to review the following:
o Microtrol drug delivery technology used in Adderall XR
Shire Pharmaceuticals Group plc
Hampshire International Business Park,
Chineham, Basingstoke RG24 8EP UK
Tel +44 1256 894000 Fax +44 1256 894708
http://www.shire.com
o Adderall XR data presented at the APA
o Shire clinical programs for Adderall XR in adult ADHD
For those unable to attend the meeting in person, a conference call facility
will be made available. All investors are invited to take part in this meeting,
and are required to pre-register with the company by 5:00pm ET on Friday May 17,
2002. Specific details regarding the investor meeting and conference call will
be provided upon pre-registration.
Pre-registration contacts: North America: Carole Archambault
Tel: 450-978-7938
Email: carchambault@ca.shire.com
Europe and Other: Souheil Salah
Tel: 44 1256 894 160
Email: ssalah@uk.shire.com
- --------------------------------------------------------------------------------
APA Event Details:
Date: Tuesday, May 21, 2002
Time: 11:00am to 12:30pm ET
Location: Convention Center, Street Level, Room 113C
Title: Long-Term Safety and Efficacy of Adderall Extended
Release in Children with ADHD
Primary Author: Chandler, Mark C., M.D
Date: Wednesday, May 22, 2002
Time: 12:00pm to 2:00pm ET
Location: Convention Center, Street Level, Exhibit Hall D
Title: An Open-Label, Community Assessment Trial of
Adderall XR in Pediatric ADHD
Primary Author: Ambrosini, Paul J., M.D.
Date: Wednesday, May 22, 2002
Time: 7:00pm to 10:00pm ET
Location: Marriott, Level 5, Grand Ballroom, Salons G/H
Title: Adult ADHD: From Research to Clinical Practice
Shire Pharmaceuticals Group plc
Hampshire International Business Park,
Chineham, Basingstoke RG24 8EP UK
Tel +44 1256 894000 Fax +44 1256 894708
http://www.shire.com
Chairperson: Biederman, Joseph, M.D.
Co-Chairperson: Spencer, Thomas J., M.D.
-end-
For further information please contact:
Global (outside US and Canada)
Clea Rosenfeld - Investor Relations +44 1256 894 160
Jessica Mann - Media +44 1256 894 280
US & Canada
Gordon Ngan - Investor Relations +1 450 978 7938
Michele Roy - Media +1 450 978 7938
Notes to editors
This news release is intended for broadcast to members of the financial
community only.
Shire Pharmaceuticals Group plc
Shire is an international specialty pharmaceutical company with a strategic
focus on three therapeutic areas - central nervous system disorders, oncology
and anti-infectives. Shire's core strategy is based on research and development
combined with in-licensing and a focus on eight key pharmaceutical markets.
For further information on Shire, please visit the company's website:
www.shire.com
THE "SAFE HARBOUR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT
OF 1995. The statements in this press release that are not historical facts are
forward-looking statements. Such forward-looking statements involve a number of
risks and uncertainties and are subject to change at any time. In the event that
such risks or uncertainties materialise, Shire's results could be materially
affected. The risks and uncertainties include, but are not limited to, risks
associated with the inherent uncertainty of pharmaceutical research, product
development and commercialisation, the impact of competitive products, patents,
government regulation and approval, and other risks and uncertainties detailed
from time to time in periodic reports produced by Shire, including the Annual
Report filed on Form 10K by Shire with the Securities and Exchange Commission.